Vir is holding off on advancing the combination therapy to Phase III trials until it secures a development partner.

A new report released today by the World Hepatitis Alliance (WHA) reveals widespread knowledge gaps, inequities in access, ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

The "Hepatitis B - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.This report outlays comprehensive insights of present clinical development scenario and ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Patients attending Medway Maritime Hospital's A&E will now be routinely tested for HIV and hepatitis unless they opt out. The ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

and hepatitis B virus (HBV) DNA titers below the lower limit of detection (LLOD), is associated with better clinical outcomes of chronic HBV infection and is regarded as the preferred treatment ...

Understanding how to prevent Hepatitis is key to maintaining liver health and protecting communities. Let’s break it down ...

Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when ...

Liver disease patients are falling through the cracks and not getting the treatment they need. Support from people with lived ...